BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lenbelintide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lenbelintide\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06151964-149@assetmemo.bio
DTSTAMP:20261121T004542Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Lenbelintide: Phase 1/2 readout est. (NCT06151964)
DESCRIPTION:Lenbelintide\, phase 1/2\, Obesity.\nStudy: A Trial to Learn Ho
 w Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or 
 Without Type 2 Diabetes Who Are Living With Obesity and Overweight\nEstima
 ted primary completion: 29 January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/lenbelintide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06151964
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07546760-149@assetmemo.bio
DTSTAMP:20261121T004542Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:Lenbelintide: Phase 1 readout est. (NCT07546760)
DESCRIPTION:Lenbelintide\, phase 1.\nStudy: A Phase I Study to Investigate 
 the Effect of Hepatic Impairment of AZD9550 and AZD6234\nEstimated primary
  completion: 4 February 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/lenbelintide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07546760
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911514-149@assetmemo.bio
DTSTAMP:20261121T004542Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Lenbelintide: Phase 1 readout est. (NCT07911514)
DESCRIPTION:Lenbelintide\, phase 1.\nStudy: A Trial to Assess the Relative 
 Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6
 234\nEstimated primary completion: 4 May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/lenbelintide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07911514
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013643-149@assetmemo.bio
DTSTAMP:20261121T004542Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:Lenbelintide: Phase 1 readout est. (NCT07013643)
DESCRIPTION:Lenbelintide\, phase 1\, Obesity.\nStudy: A Study to Investigat
 e the Effect of AZD6234\, AZD9550\, and a Combination of AZD9550 and AZD62
 34 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Le
 vonorgestrel in Healthy Female Participants Living With Overweight or Obes
 ity\nEstimated primary completion: 9 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/lenbelintide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07013643
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784270-149@assetmemo.bio
DTSTAMP:20261121T004542Z
DTSTART;VALUE=DATE:20280809
DTEND;VALUE=DATE:20280810
SUMMARY:Lenbelintide: Phase 3 readout est. (NCT07784270)
DESCRIPTION:Lenbelintide\, phase 3\, Obesity.\nStudy: A Study to Evaluate E
 ffect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and O
 besity or Overweight\nEstimated primary completion: 9 August 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/lenbelintide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07784270
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776509-149@assetmemo.bio
DTSTAMP:20261121T004542Z
DTSTART;VALUE=DATE:20280809
DTEND;VALUE=DATE:20280810
SUMMARY:Lenbelintide: Phase 3 readout est. (NCT07776509)
DESCRIPTION:Lenbelintide\, phase 3\, Obesity.\nStudy: A Study to Evaluate E
 ffect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Partic
 ipants With Obesity or Overweight With Weight-related Comorbidity With or 
 Without Type 2 Diabetes Mellitus\nEstimated primary completion: 9 August 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/lenbelintide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0777650
 9
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784725-149@assetmemo.bio
DTSTAMP:20261121T004542Z
DTSTART;VALUE=DATE:20280811
DTEND;VALUE=DATE:20280812
SUMMARY:Lenbelintide: Phase 3 readout est. (NCT07784725)
DESCRIPTION:Lenbelintide\, phase 3\, Obesity.\nStudy: A Study to Evaluate E
 ffect of AZD6234 in Adult Participants With Obesity or Overweight With Wei
 ght-related Comorbidity Without Type 2 Diabetes Mellitus\nEstimated primar
 y completion: 11 August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/lenbelintide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07784725
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07922330-149@assetmemo.bio
DTSTAMP:20261121T004542Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Lenbelintide: Phase 3 readout est. (NCT07922330)
DESCRIPTION:Lenbelintide\, phase 3\, Obesity.\nStudy: A Study to Evaluate t
 he Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adu
 lts Who Are Obese or Overweight. These Participants May or May Not Also Ha
 ve Type 2 Diabetes\nEstimated primary completion: 15 September 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lenbelintide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07922330
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
